Thalidomide, a selective inhibitor of tumor necrosis factor a (TNF-a) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of the ceils to recombinant TNF-a, phorbol myristate acetate, lipopolysaccharide, and other cytokine combinations. Associated with HIV-1 inhibition is a reduction in agonist-induced TNF-a protein and mRNA production. Thalidomide inhibition of vims replication in the phorbol myristate acetate-and recombinant TNF-a-stimulated T-ceil line ACH-2 is not observed. The presence of thalidomide also Inhibits the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. These results suggest the use of thalidomide in a clinical setting to inhibit both virus replication and the TNF-a-induced systemic toxicity of HIV-1 and opportunistic infectious.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.